Haemodynamic effects of propranolol in hypertension: a review. 1976

R C Tarazi, and H P Dustan, and E L Bravo

Like hypertension which is a multifactorial disease, the blood pressure response to propranolol cannot be explained by one mechanism alone to the exclusion of all others. Acute (intravenous) administration of propranolol lowers cardiac output and slows heart rate but does not significantly alter blood pressure. With continued therapy however, blood pressure (in responders) is gradually reduced while cardiac output and rate remains low, indicating a readaptation of total peripheral resistance (TPR) to the new haemodynamic conditions. This relatively complex interplay of factors and the predominant role of TPR in blood pressure response help explain why haemodynamic indices (such as elevated heart rate and cardiac output) were found of little value in predicting response to therapy and the failure of propranolol to control transient pressor responses associated with stress; although the increase of output in response to stress was blocked pressure rose due to increase in TPR. Therefore, despite the obvious cardiac effects of beta-adrenergic blockade, a blood pressure response to propranolol cannot be used as an index of cardiac participation in that hypertension. The long-term changes in TPR were significantly (P less than 0-02) correlated with reduction in plasma renin activity (PRA). This association does not necessarily imply a causal relationship since PRA suppression occurs at lower doses and much more rapidly than alterations in blood pressure. Further, the hypotensive effect obtained by adding propranolol to diuretic therapy was not associated with a significant reduction in PRA. However, the absence of correlation in a group of patients between blood pressure response to propranolol and its effect on other biological variables does not mean that these variables have no role in the hypotensive response. In fact, in some specific conditions the change in one variable might assume particular importance; thus in the markedly hyperkinetic circulation induced by potent vasodilators, reducing cardiac rate and output may play a major role in controlling persistent hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008914 Minoxidil A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) Loniten,Regaine,Rogaine,U 10858
D010953 Plasma Volume Volume of PLASMA in the circulation. It is usually measured by INDICATOR DILUTION TECHNIQUES. Blood Plasma Volume,Blood Plasma Volumes,Plasma Volumes,Volume, Blood Plasma,Volume, Plasma,Volumes, Blood Plasma,Volumes, Plasma
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001775 Blood Circulation The movement of the BLOOD as it is pumped through the CARDIOVASCULAR SYSTEM. Blood Flow,Circulation, Blood,Blood Flows,Flow, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

R C Tarazi, and H P Dustan, and E L Bravo
April 1967, British medical journal,
R C Tarazi, and H P Dustan, and E L Bravo
January 1986, European journal of clinical pharmacology,
R C Tarazi, and H P Dustan, and E L Bravo
August 1967, Clinical science,
R C Tarazi, and H P Dustan, and E L Bravo
January 1970, Thorax,
R C Tarazi, and H P Dustan, and E L Bravo
January 1968, Acta cardiologica,
R C Tarazi, and H P Dustan, and E L Bravo
January 1967, British medical journal,
R C Tarazi, and H P Dustan, and E L Bravo
May 1984, European heart journal,
R C Tarazi, and H P Dustan, and E L Bravo
August 1984, Clinical science (London, England : 1979),
R C Tarazi, and H P Dustan, and E L Bravo
January 1976, Postgraduate medical journal,
Copied contents to your clipboard!